» Articles » PMID: 24916062

Molecular Insight of Isotypes Specific β-tubulin Interaction of Tubulin Heterodimer with Noscapinoids

Overview
Publisher Springer
Date 2014 Jun 12
PMID 24916062
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Noscapine and its derivatives bind stoichiometrically to tubulin, alter its dynamic instability and thus effectively inhibit the cellular proliferation of a wide variety of cancer cells including many drug-resistant variants. The tubulin molecule is composed of α- and β-tubulin, which exist as various isotypes whose distribution and drug-binding properties are significantly different. Although the noscapinoids bind to a site overlapping with colchicine, their interaction is more biased towards β-tubulin. In fact, their precise interaction and binding affinity with specific isotypes of β-tubulin in the αβ-heterodimer has never been addressed. In this study, the binding affinity of a panel of noscapinoids with each type of tubulin was investigated computationally. We found that the binding score of a specific noscapinoid with each type of tubulin isotype is different. Specifically, amino-noscapine has the highest binding score of -6.4, -7.2, -7.4 and -7.3 kcal/mol with αβI, αβII, αβIII and αβIV isotypes, respectively. Similarly 10 showed higher binding affinity of -6.8 kcal/mol with αβV, whereas 8 had the highest binding affinity of -7.2, -7.1 and -7.2 kcal/mol, respectively with αβVI, αβVII and αβVIII isotypes. More importantly, both amino-noscapine and its clinical derivative, bromo-noscapine have the highest binding affinity of -46.2 and -38.1 kcal/mol against αβIII (overexpression of αβIII has been associated with resistance to a wide range of chemotherapeutic drugs for several human malignancies) as measured using MM-PBSA. Knowledge of the isotype specificity of the noscapinoids may allow for development of novel therapeutic agents based on this class of drugs.

Citing Articles

Effects of codon optimization, N-terminal truncation and gene dose on the heterologous expression of berberine bridge enzyme.

Xu Z, Xia L, Sun M, Huang P, Zeng J World J Microbiol Biotechnol. 2022; 38(5):77.

PMID: 35316417 DOI: 10.1007/s11274-022-03265-w.


Investigations of the Mode of Action of Novel Colchicine Derivatives Targeting β-Tubulin Isotypes: A Search for a Selective and Specific β-III Tubulin Ligand.

Pallante L, Rocca A, Klejborowska G, Huczynski A, Grasso G, Tuszynski J Front Chem. 2020; 8:108.

PMID: 32154219 PMC: 7047339. DOI: 10.3389/fchem.2020.00108.


Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia.

Cury N, Muhlethaler T, Laranjeira A, Canevarolo R, Zenatti P, Lucena-Agell D iScience. 2019; 21:95-109.

PMID: 31655259 PMC: 6820235. DOI: 10.1016/j.isci.2019.10.003.


Recent Developments and Applications of the MMPBSA Method.

Wang C, Greene D, Xiao L, Qi R, Luo R Front Mol Biosci. 2018; 4:87.

PMID: 29367919 PMC: 5768160. DOI: 10.3389/fmolb.2017.00087.


Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.

Kumbhar B, Borogaon A, Panda D, Kunwar A PLoS One. 2016; 11(5):e0156048.

PMID: 27227832 PMC: 4882049. DOI: 10.1371/journal.pone.0156048.


References
1.
Torin Huzil J, Luduena R, Tuszynski J . Comparative modelling of human β tubulin isotypes and implications for drug binding. Nanotechnology. 2011; 17(4):S90-S100. DOI: 10.1088/0957-4484/17/4/014. View

2.
Banerjee A, Luduena R . Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem. 1992; 267(19):13335-9. View

3.
Landen J, Lang R, McMahon S, Rusan N, Adams A, Sorcinelli M . Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 2002; 62(14):4109-14. View

4.
Checchi P, Nettles J, Zhou J, Snyder J, Joshi H . Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci. 2003; 24(7):361-5. DOI: 10.1016/S0165-6147(03)00161-5. View

5.
Downing K . Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol. 2000; 16:89-111. DOI: 10.1146/annurev.cellbio.16.1.89. View